nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—Kawasaki disease	0.589	1	CbGaD
Carvedilol—PTGS1—Acetylsalicylic acid—Kawasaki disease	0.0986	0.558	CbGbCtD
Carvedilol—CYP2C9—Acetylsalicylic acid—Kawasaki disease	0.0397	0.224	CbGbCtD
Carvedilol—ABCB1—Acetylsalicylic acid—Kawasaki disease	0.0385	0.218	CbGbCtD
Carvedilol—Respiratory alkalosis—Acetylsalicylic acid—Kawasaki disease	0.0168	0.209	CcSEcCtD
Carvedilol—VCAM1—tunica intima—Kawasaki disease	0.0101	0.0912	CbGeAlD
Carvedilol—SELE—umbilical vein—Kawasaki disease	0.00671	0.0604	CbGeAlD
Carvedilol—VCAM1—umbilical vein—Kawasaki disease	0.00617	0.0556	CbGeAlD
Carvedilol—KCNH2—endocardium—Kawasaki disease	0.00616	0.0555	CbGeAlD
Carvedilol—Diabetic—Acetylsalicylic acid—Kawasaki disease	0.0058	0.0722	CcSEcCtD
Carvedilol—NPPB—artery—Kawasaki disease	0.00557	0.0502	CbGeAlD
Carvedilol—Breast feeding—Acetylsalicylic acid—Kawasaki disease	0.00554	0.069	CcSEcCtD
Carvedilol—Clotting—Acetylsalicylic acid—Kawasaki disease	0.00542	0.0675	CcSEcCtD
Carvedilol—Kidney function abnormal—Acetylsalicylic acid—Kawasaki disease	0.00401	0.0499	CcSEcCtD
Carvedilol—SELE—artery—Kawasaki disease	0.00376	0.0339	CbGeAlD
Carvedilol—VCAM1—artery—Kawasaki disease	0.00346	0.0312	CbGeAlD
Carvedilol—HIF1A—artery—Kawasaki disease	0.00333	0.03	CbGeAlD
Carvedilol—GJA1—artery—Kawasaki disease	0.00323	0.0291	CbGeAlD
Carvedilol—VCAM1—Beta2 integrin cell surface interactions—FCGR2A—Kawasaki disease	0.00318	0.0739	CbGpPWpGaD
Carvedilol—SELE—endothelium—Kawasaki disease	0.00318	0.0286	CbGeAlD
Carvedilol—NPPB—cardiac ventricle—Kawasaki disease	0.00313	0.0282	CbGeAlD
Carvedilol—VCAM1—Integrin cell surface interactions—ITGAE—Kawasaki disease	0.00301	0.0699	CbGpPWpGaD
Carvedilol—NPPB—myocardium—Kawasaki disease	0.00294	0.0265	CbGeAlD
Carvedilol—VCAM1—endothelium—Kawasaki disease	0.00293	0.0264	CbGeAlD
Carvedilol—HIF1A—endothelium—Kawasaki disease	0.00281	0.0254	CbGeAlD
Carvedilol—SELE—Thromboxane A2 receptor signaling—BLK—Kawasaki disease	0.00277	0.0642	CbGpPWpGaD
Carvedilol—GJA1—endothelium—Kawasaki disease	0.00273	0.0246	CbGeAlD
Carvedilol—Coagulopathy—Acetylsalicylic acid—Kawasaki disease	0.00249	0.031	CcSEcCtD
Carvedilol—HIF1A—gall bladder—Kawasaki disease	0.00244	0.022	CbGeAlD
Carvedilol—HIF1A—miR-148a/miR-31/FIH1/HIF1α-Notch signaling in glioblastoma —VEGFA—Kawasaki disease	0.00241	0.056	CbGpPWpGaD
Carvedilol—Gout—Acetylsalicylic acid—Kawasaki disease	0.00207	0.0258	CcSEcCtD
Carvedilol—NPPB—heart—Kawasaki disease	0.00205	0.0185	CbGeAlD
Carvedilol—Hearing impaired—Acetylsalicylic acid—Kawasaki disease	0.00203	0.0253	CcSEcCtD
Carvedilol—SELE—myocardium—Kawasaki disease	0.00199	0.0179	CbGeAlD
Carvedilol—HIF1A—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—Kawasaki disease	0.00197	0.0458	CbGpPWpGaD
Carvedilol—VCAM1—neck—Kawasaki disease	0.00193	0.0174	CbGeAlD
Carvedilol—Melaena—Acetylsalicylic acid—Kawasaki disease	0.00189	0.0236	CcSEcCtD
Carvedilol—HIF1A—cardiac ventricle—Kawasaki disease	0.00187	0.0168	CbGeAlD
Carvedilol—HIF1A—neck—Kawasaki disease	0.00186	0.0167	CbGeAlD
Carvedilol—VCAM1—myocardium—Kawasaki disease	0.00183	0.0165	CbGeAlD
Carvedilol—VCAM1—Thromboxane A2 receptor signaling—BLK—Kawasaki disease	0.00182	0.0423	CbGpPWpGaD
Carvedilol—GJA1—cardiac ventricle—Kawasaki disease	0.00181	0.0163	CbGeAlD
Carvedilol—GJA1—neck—Kawasaki disease	0.0018	0.0162	CbGeAlD
Carvedilol—HIF1A—myocardium—Kawasaki disease	0.00176	0.0158	CbGeAlD
Carvedilol—Lightheadedness—Acetylsalicylic acid—Kawasaki disease	0.00173	0.0216	CcSEcCtD
Carvedilol—GJA1—myocardium—Kawasaki disease	0.00171	0.0154	CbGeAlD
Carvedilol—Diabetes mellitus—Acetylsalicylic acid—Kawasaki disease	0.00162	0.0201	CcSEcCtD
Carvedilol—Vascular purpura—Acetylsalicylic acid—Kawasaki disease	0.00157	0.0196	CcSEcCtD
Carvedilol—NDUFC2—neck—Kawasaki disease	0.00157	0.0141	CbGeAlD
Carvedilol—Renal impairment—Acetylsalicylic acid—Kawasaki disease	0.00148	0.0184	CcSEcCtD
Carvedilol—Purpura—Acetylsalicylic acid—Kawasaki disease	0.00146	0.0182	CcSEcCtD
Carvedilol—Hypoglycaemia—Acetylsalicylic acid—Kawasaki disease	0.00144	0.0179	CcSEcCtD
Carvedilol—VEGFA—cardiac ventricle—Kawasaki disease	0.00143	0.0129	CbGeAlD
Carvedilol—Gastrointestinal haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.00141	0.0175	CcSEcCtD
Carvedilol—SELE—heart—Kawasaki disease	0.00139	0.0125	CbGeAlD
Carvedilol—SELE—skin of body—Kawasaki disease	0.00136	0.0122	CbGeAlD
Carvedilol—VEGFA—myocardium—Kawasaki disease	0.00135	0.0121	CbGeAlD
Carvedilol—VEGFA—Glypican 1 network—BLK—Kawasaki disease	0.00129	0.0299	CbGpPWpGaD
Carvedilol—Hypokalaemia—Acetylsalicylic acid—Kawasaki disease	0.00128	0.0159	CcSEcCtD
Carvedilol—VCAM1—heart—Kawasaki disease	0.00128	0.0115	CbGeAlD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD40—Kawasaki disease	0.00127	0.0294	CbGpPWpGaD
Carvedilol—HIF1A—heart—Kawasaki disease	0.00123	0.0111	CbGeAlD
Carvedilol—Influenza—Acetylsalicylic acid—Kawasaki disease	0.00121	0.0151	CcSEcCtD
Carvedilol—HIF1A—skin of body—Kawasaki disease	0.0012	0.0108	CbGeAlD
Carvedilol—GJA1—heart—Kawasaki disease	0.00119	0.0107	CbGeAlD
Carvedilol—GJA1—skin of body—Kawasaki disease	0.00117	0.0105	CbGeAlD
Carvedilol—NDUFC2—heart—Kawasaki disease	0.00104	0.00933	CbGeAlD
Carvedilol—HIF1A—Angiogenesis—MMP9—Kawasaki disease	0.001	0.0233	CbGpPWpGaD
Carvedilol—VCAM1—Extracellular matrix organization—ITGAE—Kawasaki disease	0.000992	0.023	CbGpPWpGaD
Carvedilol—VCAM1—Alpha9 beta1 integrin signaling events—VEGFA—Kawasaki disease	0.000983	0.0228	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—ITPKC—Kawasaki disease	0.000979	0.0227	CbGpPWpGaD
Carvedilol—Haemoglobin—Acetylsalicylic acid—Kawasaki disease	0.000977	0.0122	CcSEcCtD
Carvedilol—Haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.000972	0.0121	CcSEcCtD
Carvedilol—GJA1—Spinal Cord Injury—FCGR2A—Kawasaki disease	0.000951	0.0221	CbGpPWpGaD
Carvedilol—VEGFA—heart—Kawasaki disease	0.00094	0.00847	CbGeAlD
Carvedilol—Tinnitus—Acetylsalicylic acid—Kawasaki disease	0.000906	0.0113	CcSEcCtD
Carvedilol—HIF1A—Angiogenesis—VEGFA—Kawasaki disease	0.0009	0.0209	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—IL10—Kawasaki disease	0.000893	0.0207	CbGpPWpGaD
Carvedilol—HIF1A—Cellular response to hypoxia—VEGFA—Kawasaki disease	0.000871	0.0202	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—IL10—Kawasaki disease	0.000861	0.02	CbGpPWpGaD
Carvedilol—Anaemia—Acetylsalicylic acid—Kawasaki disease	0.000782	0.00974	CcSEcCtD
Carvedilol—HIF1A—VEGFR1 specific signals—VEGFA—Kawasaki disease	0.000774	0.018	CbGpPWpGaD
Carvedilol—Angioedema—Acetylsalicylic acid—Kawasaki disease	0.000773	0.00963	CcSEcCtD
Carvedilol—Vertigo—Acetylsalicylic acid—Kawasaki disease	0.00076	0.00947	CcSEcCtD
Carvedilol—Syncope—Acetylsalicylic acid—Kawasaki disease	0.000759	0.00945	CcSEcCtD
Carvedilol—Leukopenia—Acetylsalicylic acid—Kawasaki disease	0.000758	0.00944	CcSEcCtD
Carvedilol—Loss of consciousness—Acetylsalicylic acid—Kawasaki disease	0.000744	0.00927	CcSEcCtD
Carvedilol—GJA1—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—Kawasaki disease	0.000735	0.0171	CbGpPWpGaD
Carvedilol—Convulsion—Acetylsalicylic acid—Kawasaki disease	0.000733	0.00913	CcSEcCtD
Carvedilol—Hypertension—Acetylsalicylic acid—Kawasaki disease	0.000731	0.0091	CcSEcCtD
Carvedilol—Chest pain—Acetylsalicylic acid—Kawasaki disease	0.000721	0.00897	CcSEcCtD
Carvedilol—Arthralgia—Acetylsalicylic acid—Kawasaki disease	0.000721	0.00897	CcSEcCtD
Carvedilol—Confusional state—Acetylsalicylic acid—Kawasaki disease	0.000696	0.00867	CcSEcCtD
Carvedilol—Anaphylactic shock—Acetylsalicylic acid—Kawasaki disease	0.000691	0.0086	CcSEcCtD
Carvedilol—PTGS1—artery—Kawasaki disease	0.000686	0.00618	CbGeAlD
Carvedilol—Shock—Acetylsalicylic acid—Kawasaki disease	0.00068	0.00846	CcSEcCtD
Carvedilol—ADRB1—cardiac ventricle—Kawasaki disease	0.000679	0.00612	CbGeAlD
Carvedilol—Thrombocytopenia—Acetylsalicylic acid—Kawasaki disease	0.000676	0.00842	CcSEcCtD
Carvedilol—Tachycardia—Acetylsalicylic acid—Kawasaki disease	0.000674	0.0084	CcSEcCtD
Carvedilol—HIF1A—Notch-mediated HES/HEY network—CD4—Kawasaki disease	0.000672	0.0156	CbGpPWpGaD
Carvedilol—Hyperhidrosis—Acetylsalicylic acid—Kawasaki disease	0.000668	0.00832	CcSEcCtD
Carvedilol—ADRB1—myocardium—Kawasaki disease	0.000639	0.00576	CbGeAlD
Carvedilol—Dyspnoea—Acetylsalicylic acid—Kawasaki disease	0.000616	0.00767	CcSEcCtD
Carvedilol—Somnolence—Acetylsalicylic acid—Kawasaki disease	0.000614	0.00765	CcSEcCtD
Carvedilol—Dyspepsia—Acetylsalicylic acid—Kawasaki disease	0.000608	0.00757	CcSEcCtD
Carvedilol—PTGS1—endothelium—Kawasaki disease	0.00058	0.00522	CbGeAlD
Carvedilol—Feeling abnormal—Acetylsalicylic acid—Kawasaki disease	0.000569	0.00709	CcSEcCtD
Carvedilol—Urticaria—Acetylsalicylic acid—Kawasaki disease	0.000549	0.00683	CcSEcCtD
Carvedilol—KCNH2—cardiac ventricle—Kawasaki disease	0.000519	0.00467	CbGeAlD
Carvedilol—ADRA2C—cardiac ventricle—Kawasaki disease	0.000512	0.00461	CbGeAlD
Carvedilol—Hypersensitivity—Acetylsalicylic acid—Kawasaki disease	0.000509	0.00634	CcSEcCtD
Carvedilol—VEGFA—Focal Adhesion—ITGAE—Kawasaki disease	0.000494	0.0115	CbGpPWpGaD
Carvedilol—Pruritus—Acetylsalicylic acid—Kawasaki disease	0.000489	0.00609	CcSEcCtD
Carvedilol—KCNH2—myocardium—Kawasaki disease	0.000488	0.0044	CbGeAlD
Carvedilol—PTGS1—Overview of nanoparticle effects—CRP—Kawasaki disease	0.000487	0.0113	CbGpPWpGaD
Carvedilol—ADRA2C—myocardium—Kawasaki disease	0.000481	0.00434	CbGeAlD
Carvedilol—Diarrhoea—Acetylsalicylic acid—Kawasaki disease	0.000473	0.00589	CcSEcCtD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL10—Kawasaki disease	0.00047	0.0109	CbGpPWpGaD
Carvedilol—Dizziness—Acetylsalicylic acid—Kawasaki disease	0.000457	0.00569	CcSEcCtD
Carvedilol—NDUFC2—Metabolism—ITPKC—Kawasaki disease	0.000454	0.0105	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL10—Kawasaki disease	0.000453	0.0105	CbGpPWpGaD
Carvedilol—VCAM1—Beta1 integrin cell surface interactions—VEGFA—Kawasaki disease	0.000452	0.0105	CbGpPWpGaD
Carvedilol—HIF1A—AGE/RAGE pathway—MMP9—Kawasaki disease	0.000446	0.0104	CbGpPWpGaD
Carvedilol—ADRB1—heart—Kawasaki disease	0.000446	0.00402	CbGeAlD
Carvedilol—GJA1—AP-1 transcription factor network—MMP9—Kawasaki disease	0.000441	0.0103	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—CD40—Kawasaki disease	0.00044	0.0102	CbGpPWpGaD
Carvedilol—Vomiting—Acetylsalicylic acid—Kawasaki disease	0.000439	0.00547	CcSEcCtD
Carvedilol—CYP1A1—cardiac ventricle—Kawasaki disease	0.000438	0.00395	CbGeAlD
Carvedilol—Rash—Acetylsalicylic acid—Kawasaki disease	0.000436	0.00542	CcSEcCtD
Carvedilol—Dermatitis—Acetylsalicylic acid—Kawasaki disease	0.000435	0.00542	CcSEcCtD
Carvedilol—VEGFA—Angiogenesis—MMP9—Kawasaki disease	0.000433	0.01	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—MMP9—Kawasaki disease	0.000426	0.00989	CbGpPWpGaD
Carvedilol—Nausea—Acetylsalicylic acid—Kawasaki disease	0.00041	0.00511	CcSEcCtD
Carvedilol—HIF1A—Oncostatin M Signaling Pathway—VEGFA—Kawasaki disease	0.000406	0.00942	CbGpPWpGaD
Carvedilol—HIF1A—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	0.000401	0.0093	CbGpPWpGaD
Carvedilol—PTGS1—myocardium—Kawasaki disease	0.000362	0.00326	CbGeAlD
Carvedilol—ADRA1A—heart—Kawasaki disease	0.000353	0.00318	CbGeAlD
Carvedilol—KCNH2—heart—Kawasaki disease	0.000341	0.00307	CbGeAlD
Carvedilol—VEGFA—Allograft Rejection—IL10—Kawasaki disease	0.000337	0.00783	CbGpPWpGaD
Carvedilol—ADRA2C—heart—Kawasaki disease	0.000336	0.00303	CbGeAlD
Carvedilol—XDH—Selenium Micronutrient Network—CRP—Kawasaki disease	0.000305	0.00709	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—MMP9—Kawasaki disease	0.000291	0.00675	CbGpPWpGaD
Carvedilol—CYP1A1—heart—Kawasaki disease	0.000288	0.00259	CbGeAlD
Carvedilol—CYP1A1—skin of body—Kawasaki disease	0.000282	0.00254	CbGeAlD
Carvedilol—CYP2C9—heart—Kawasaki disease	0.000277	0.00249	CbGeAlD
Carvedilol—VCAM1—Adaptive Immune System—BLK—Kawasaki disease	0.000271	0.00629	CbGpPWpGaD
Carvedilol—ADRA2A—heart—Kawasaki disease	0.000268	0.00242	CbGeAlD
Carvedilol—VEGFA—Focal Adhesion—BLK—Kawasaki disease	0.000262	0.00609	CbGpPWpGaD
Carvedilol—PTGS1—heart—Kawasaki disease	0.000253	0.00228	CbGeAlD
Carvedilol—PTGS1—skin of body—Kawasaki disease	0.000247	0.00223	CbGeAlD
Carvedilol—VCAM1—Adaptive Immune System—CD40—Kawasaki disease	0.000225	0.00523	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—VEGFA—Kawasaki disease	0.000209	0.00485	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—VEGFA—Kawasaki disease	0.000201	0.00468	CbGpPWpGaD
Carvedilol—VEGFA—Endochondral Ossification—MMP9—Kawasaki disease	0.000197	0.00458	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL10—Kawasaki disease	0.000196	0.00454	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Other—CCR5—Kawasaki disease	0.000178	0.00413	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL10—Kawasaki disease	0.000177	0.00412	CbGpPWpGaD
Carvedilol—XDH—Metabolism—ITPKC—Kawasaki disease	0.000177	0.00411	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—FCGR2A—Kawasaki disease	0.000169	0.00393	CbGpPWpGaD
Carvedilol—VCAM1—Extracellular matrix organization—MMP9—Kawasaki disease	0.000166	0.00386	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—BLK—Kawasaki disease	0.000164	0.00382	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Other—CCR5—Kawasaki disease	0.000158	0.00368	CbGpPWpGaD
Carvedilol—ABCB1—heart—Kawasaki disease	0.000149	0.00135	CbGeAlD
Carvedilol—VEGFA—EPH-Ephrin signaling—MMP9—Kawasaki disease	0.000145	0.00337	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—CRP—Kawasaki disease	0.000143	0.00332	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD40—Kawasaki disease	0.000137	0.00317	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CD40—Kawasaki disease	0.000136	0.00316	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—VEGFA—Kawasaki disease	0.000134	0.00312	CbGpPWpGaD
Carvedilol—HIF1A—Cellular responses to stress—VEGFA—Kawasaki disease	0.000132	0.00307	CbGpPWpGaD
Carvedilol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	0.000119	0.00275	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—MMP9—Kawasaki disease	0.000107	0.00248	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL10—Kawasaki disease	0.000104	0.00242	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	0.000102	0.00236	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD4—Kawasaki disease	9.8e-05	0.00228	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	8.93e-05	0.00208	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CRP—Kawasaki disease	8.8e-05	0.00204	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ITPKC—Kawasaki disease	8.31e-05	0.00193	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ITPKC—Kawasaki disease	8.29e-05	0.00193	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—VEGFA—Kawasaki disease	7.88e-05	0.00183	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CCR5—Kawasaki disease	7.74e-05	0.0018	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—CCR5—Kawasaki disease	7.74e-05	0.0018	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	7.72e-05	0.00179	CbGpPWpGaD
Carvedilol—ADRA2B—G alpha (i) signalling events—CCR5—Kawasaki disease	7.51e-05	0.00174	CbGpPWpGaD
Carvedilol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	7.04e-05	0.00163	CbGpPWpGaD
Carvedilol—ADRA2C—G alpha (i) signalling events—CCR5—Kawasaki disease	7.02e-05	0.00163	CbGpPWpGaD
Carvedilol—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	6.97e-05	0.00162	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	6.88e-05	0.0016	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ITPKC—Kawasaki disease	6.75e-05	0.00157	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	6.62e-05	0.00154	CbGpPWpGaD
Carvedilol—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	6.51e-05	0.00151	CbGpPWpGaD
Carvedilol—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	6.41e-05	0.00149	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ITPKC—Kawasaki disease	6.2e-05	0.00144	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	6.03e-05	0.0014	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	5.97e-05	0.00139	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD4—Kawasaki disease	5.94e-05	0.00138	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	5.9e-05	0.00137	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ITPKC—Kawasaki disease	5.84e-05	0.00136	CbGpPWpGaD
Carvedilol—ADRA2A—G alpha (i) signalling events—CCR5—Kawasaki disease	5.7e-05	0.00132	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	5.7e-05	0.00132	CbGpPWpGaD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	5.69e-05	0.00132	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	5.58e-05	0.0013	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	5.49e-05	0.00128	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CCR5—Kawasaki disease	5.42e-05	0.00126	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—MMP9—Kawasaki disease	5.39e-05	0.00125	CbGpPWpGaD
Carvedilol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	5.35e-05	0.00124	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—Kawasaki disease	5.29e-05	0.00123	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—CCR5—Kawasaki disease	5.04e-05	0.00117	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	4.88e-05	0.00113	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CD4—Kawasaki disease	4.86e-05	0.00113	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ITPKC—Kawasaki disease	4.67e-05	0.00108	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—VEGFA—Kawasaki disease	4.63e-05	0.00108	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CCR5—Kawasaki disease	4.59e-05	0.00107	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CCR5—Kawasaki disease	4.55e-05	0.00106	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—Kawasaki disease	4.53e-05	0.00105	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CCR5—Kawasaki disease	4.49e-05	0.00104	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ITPKC—Kawasaki disease	4.4e-05	0.00102	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—CCR5—Kawasaki disease	4.37e-05	0.00102	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ITPKC—Kawasaki disease	4.36e-05	0.00101	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CCR5—Kawasaki disease	4.25e-05	0.000987	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CCR5—Kawasaki disease	4.18e-05	0.000971	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CCR5—Kawasaki disease	3.97e-05	0.000922	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	3.88e-05	0.0009	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP9—Kawasaki disease	3.85e-05	0.000894	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ITPKC—Kawasaki disease	3.72e-05	0.000865	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CCR5—Kawasaki disease	3.71e-05	0.000863	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	3.62e-05	0.000841	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CCR5—Kawasaki disease	3.45e-05	0.000802	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MMP9—Kawasaki disease	2.97e-05	0.000689	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	2.94e-05	0.000683	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ITPKC—Kawasaki disease	2.87e-05	0.000668	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CCR5—Kawasaki disease	2.85e-05	0.000661	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—VEGFA—Kawasaki disease	2.66e-05	0.000618	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CCR5—Kawasaki disease	2.59e-05	0.000603	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CCR5—Kawasaki disease	2.59e-05	0.000601	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CCR5—Kawasaki disease	2.57e-05	0.000597	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CCR5—Kawasaki disease	2.54e-05	0.000589	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CCR5—Kawasaki disease	2.4e-05	0.000558	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CCR5—Kawasaki disease	2.36e-05	0.000549	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CCR5—Kawasaki disease	2.36e-05	0.000547	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCR5—Kawasaki disease	2.34e-05	0.000545	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCR5—Kawasaki disease	2.34e-05	0.000543	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CCR5—Kawasaki disease	2.33e-05	0.000542	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CCR5—Kawasaki disease	2.3e-05	0.000535	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	2.28e-05	0.000531	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCR5—Kawasaki disease	2.18e-05	0.000506	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCR5—Kawasaki disease	2.15e-05	0.000498	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CCR5—Kawasaki disease	2.1e-05	0.000488	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—VEGFA—Kawasaki disease	2e-05	0.000464	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CCR5—Kawasaki disease	1.95e-05	0.000453	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCR5—Kawasaki disease	1.91e-05	0.000443	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—VEGFA—Kawasaki disease	1.87e-05	0.000433	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCR5—Kawasaki disease	1.77e-05	0.000411	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCR5—Kawasaki disease	1.53e-05	0.000355	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—VEGFA—Kawasaki disease	1.52e-05	0.000352	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCR5—Kawasaki disease	1.39e-05	0.000323	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCR5—Kawasaki disease	1.38e-05	0.00032	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCR5—Kawasaki disease	1.36e-05	0.000316	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCR5—Kawasaki disease	1.29e-05	0.000299	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—Kawasaki disease	1.28e-05	0.000298	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—Kawasaki disease	1.28e-05	0.000297	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCR5—Kawasaki disease	1.27e-05	0.000294	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—VEGFA—Kawasaki disease	1.15e-05	0.000267	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCR5—Kawasaki disease	1.13e-05	0.000262	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCR5—Kawasaki disease	1.05e-05	0.000243	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—Kawasaki disease	8.35e-06	0.000194	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—Kawasaki disease	7.61e-06	0.000177	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—Kawasaki disease	7.54e-06	0.000175	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—Kawasaki disease	7.5e-06	0.000174	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—Kawasaki disease	7.45e-06	0.000173	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—Kawasaki disease	7.04e-06	0.000164	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—Kawasaki disease	6.93e-06	0.000161	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—Kawasaki disease	6.83e-06	0.000159	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—Kawasaki disease	6.77e-06	0.000157	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—Kawasaki disease	6.69e-06	0.000155	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—Kawasaki disease	6.33e-06	0.000147	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—Kawasaki disease	6.23e-06	0.000145	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—Kawasaki disease	6.16e-06	0.000143	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—Kawasaki disease	5.72e-06	0.000133	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—Kawasaki disease	5.53e-06	0.000128	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—Kawasaki disease	5.14e-06	0.000119	CbGpPWpGaD
